Dear Doctor,

Effective therapeutic management of patients enrolled in the Drug Program requires constant monitoring of their health parameters. It is a fact that the individual components of the therapeutic process for such patients should form a coherent cause-and-effect relationship, which ultimately allows for a holistic approach to their disease.

With the utmost care for the well-being of the patient and the implementation of Drug Program B.55, we are pleased to invite you to participate in a nationwide study entitled: "Clinical Perspective of Vedolizumab Application in the Drug Program <<Vedolizumab in the Treatment of Ulcerative Colitis>>. Multicenter Observational Study".

The primary objective of the study is to observe patients undergoing vedolizumab treatment and assess the effectiveness of the therapy. The collected data will be used for analysis of the study subject and preparation of a comprehensive report, which will serve as the basis for optimizing the therapeutic process.